cas 22536-63-6|| where to buy 2-Chloro-4-methoxypyrimidine

Nom du produit:2-Chloro-4-methoxypyrimidine

IUPAC Name:2-chloro-4-methoxypyrimidine

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM166431-100g	in stock	Ǚƈŗ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 22536-63-6 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:22536-63-6; Formule moléculaire:C5H5ClN2O; Point de fusion:-; Code SMILES:COC1=NC(Cl)=NC=C1; Densité:

: Numéro de catalogue:CM166431; Poids moléculaire:144.56; Point d'ébullition:268.8°C at 760 mmHg; N° Mdl:MFCD00194055; Stockage:Protect from light and store in a dry and close container at room temperature

: Pyrimidines; Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

: Risvodetinib; Inhibikase Therapeutics’s Risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. FDA for the treatment of Multiple System Atrophy (MSA). MSA is a rapidly progressive rare condition of the nervous system that causes gradual damage to nerve cells in the brain, and shares many symptoms with Parkinson's disease. This neurological disorder has an estimate an average of 0.6 to 0.7 new cases per 100,000 people yearly.
The non-receptor tyrosine kinase Abelson, c-Abl is shown to be implicated in the initiation and progression of α-synuclein (α-syn) pathogenesis and neurodegeneration. Risvodetinib is a brain-penetrant selective inhibitor of c-Abl1 and Abl2 undergoing Phase 2 clinical studies.